Who sold aBMD stock in the last quarter?
ABMD stock was sold by a variety of institutional investors in the last quarter, including Villere ST Denis J & Co. LLC, Crossmark Global Holdings Inc., State of Alaska Department of Revenue, Chicago Capital LLC, Retirement Systems of Alabama, Gulf International Bank UK Ltd, Nordea Investment Management AB, and Royal London Asset Management Ltd..
Should you hold Abiomed (aBMD) stock?
The consensus among Wall Street analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares. View analyst ratings for Abiomed or view top-rated stocks.
How can I get the latest news and ratings for aBMD?
Sign up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
What is aBMD target price?
ABMD: Lowering target price to $352.00 ABIOMED INC has an Investment Rating of HOLD; a target price of $352.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
Is ABMD stock a buy?
The consensus among 3 Wall Street analysts covering (NASDAQ: ABMD) stock is to Buy ABMD stock.
Why is Abiomed stock dropping?
Shares of heart pump company Abiomed (NSDQ:ABMD) fell today after research released over the weekend suggested potentially serious complications involving the company's Impella heart pumps.
What industry is Abiomed?
medical device companyAbiomed Inc (Abiomed) is a medical device company that develops, manufactures and markets circulatory support devices.
Is Abiomed publicly traded?
Abiomed is a publicly-traded medical devices company that develops and manufactures external and implantable circulatory support devices.
Who makes Impella heart pump?
Impella Heart Pump | OSF HealthCare.
Who are Abiomed competitors?
Abiomed's top competitors include Dong-A ST, Gerresheimer, Fresenius Kabi and Sopharma. Abiomed is a company providing medical devices for circulatory support.
Is Abiomed a Fortune 500 company?
This producer of small heart pumps hasn't missed a beat as the FDA approved Impella 2.5, a version of its flagship device for high-risk patients....Company Information.LocationDanvers, MAIndustryMedical Products & EquipmentSectorHealth CareFortune 500 Rank-Fortune 500 Profile-4 more rows
Who is the CEO of Abiomed?
Michael R. Minogue (Apr 6, 2004–)Abiomed / CEO
What does Abiomed Inc do?
Abiomed (NASDAQ: ABMD) is a leading provider of groundbreaking medical technology that provides circulatory and oxygenation support. The Impella® heart pump platform is designed to enable the heart to rest and recover by improving blood flow and/or temporarily assisting with the pumping function of the heart.
When did Abiomed go public?
1987: Applied Biomedical is merged into newly formed Abiomed, which is taken public. 1994: The National Institutes of Health (NIH) selects company to receive funding for final stage of artificial heart development.
Who invented impella?
Thorsten SiessThorsten Siess, Abiomed's Chief Technology Officer and Inventor of Impella® Shares his Insights on the Impella Platform of Heart Pumps.
What does "hold" mean in ABMD?
When is Abiomed earnings call?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares. View analyst ratings for Abiomed or view top-rated stocks.
How much does Abiomed make?
How can I listen to Abiomed's earnings call? Abiomed will be holding an earnings conference call on Thursday, August 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "5929017".
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
Abiomed has a market capitalization of $14.48 billion and generates $847.52 million in revenue each year. The medical equipment provider earns $225.52 million in net income (profit) each year or $4.94 on an earnings per share basis.
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance
DANVERS, Mass., February 08, 2022--Abiomed to present at the SVB Leerink 11th Annual Global Healthcare conference.
Shares slump after a pair of clinical studies raises new questions about the safety and cost effectiveness of Abiomed's family of heart pumps. Here are the must-know details
Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.
What happened
Brian Feroldi has been covering the healthcare and technology industries for The Motley Fool since 2015. Brian's investing strategy is to buy high-quality companies and then let compounding work its magic. See all of his articles here. Follow @brianferoldi
So what
Shares of Abiomed ( NASDAQ:ABMD) dropped about 11% as of 12:39 p.m. EST on Monday. The double-digit plunge is traceable to a pair of clinical studies that were presented over the weekend that raise new questions about the usefulness of the company's Impella heart pumps.
Now what
Two research teams presented data over the weekend at the American Heart Association's annual meeting in Philadelphia that questioned the safety and effectiveness of Abiomed's Impella heart pumps.
ABIOMED Q1 Earnings and Revenues Beat Estimates
It's understandable that shares are falling in response to this news. If Impella truly isn't as clinically effective as the intra-aortic balloon, then Abiomed's revenue and profit will likely fall substantially.
Revenues in Detail
ABIOMED, Inc . reported first-quarter fiscal 2021adjusted earnings per share of 58 cents, which beat the Zacks Consensus Estimate of 21 cents The figure declined 42% year over year.
Q1 in Detail
In the fiscal first quarter, revenues came in at $164.9 million, which beat the Zacks Consensus Estimate of $138.2 million by 19.3%. The metric however fell 20.6% from the prior-year quarter.
Margin Trend
U.S. Impella product revenues totaled $126.2 million, showing a decline of 25% year over year. Per management, U.S. patient usage of the Impella heart pumps fell 22% in the quarter, mainly due to the coronavirus pandemic.
Financial Condition
In the quarter under review, gross profit totaled $128.9 million, down 24.5% year over year. Gross margin in the quarter was 78.2% of net revenues, down 398 basis points (bps) year over year.
Fiscal 2021 Guidance
The company exited the first quarter of fiscal 2021 with $ 214.8 million of cash and cash equivalents compared with $192.3 million at the end of the previous quarter. The balance sheet was also debt free as of Jun 30, 2020.